CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

Showing 6 of 6 entries

View as:

Phase: N/A Priority: Normal

NCT ID: NCT03793088 Org: User:

Start: 02/07/19 End: 01/31/26 Due: 01/31/27

Phase: N/A Priority: Normal

NCT ID: NCT04321811 Org: User:

Start: 03/21/20 End: 03/20/21 Due: 03/20/22

Phase: N/A Priority: Normal

NCT ID: NCT06140719 Org: User:

Start: 11/01/23 End: 01/31/27 Due: 01/31/28

Phase: N/A Priority: Normal

NCT ID: NCT05052372 Org: User:

Start: 11/21/21 End: 12/20/22 Due: 12/20/23

Phase: N/A Priority: Normal

NCT ID: NCT06539169 Org: User:

Start: 06/10/24 End: 06/10/26 Due: 06/10/27

Phase: N/A Priority: Normal

NCT ID: NCT04566393 Org: User:

Start: - End: - Due: -

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Patient-Centric Platform Trial for Precision Oncology	NCT03793088	xCures	user2@example.com	None	2019-02-07	2026-01-31	2027-01-31	-	-	2025-07-14
Behavior, Environment And Treatments for Covid-19	NCT04321811	xCures	user2@example.com	None	2020-03-21	2021-03-20	2022-03-20	-	-	2025-07-14
xPedite: A Study to Expedite DIPG and DMG Research	NCT06140719	xCures	user2@example.com	None	2023-11-01	2027-01-31	2028-01-31	-	-	2025-07-14
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib	NCT05052372	xCures	user2@example.com	None	2021-11-21	2022-12-20	2023-12-20	-	-	2025-07-14
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases	NCT06539169	xCures	user2@example.com	None	2024-06-10	2026-06-10	2027-06-10	-	-	2025-07-14
Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies	NCT04566393	xCures	user2@example.com	None	-	-	-	-	-	2025-07-14